Real world data supports ciltacabtagene autoleucel as effective option for triple-class exposed r/r MM

Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with myeloma XI/XI+ Trial treatment for Uhir MM

Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted consolidation therapy gives highest rate of MRD negativity in NDMM

Latest in combination therapy for NDMM patients

Lenalidomide and rituximab as front-line chemo-free therapy for elderly frail patients with diffuse large B-cell lymphoma.

Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative neoplasm patients

Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in pts with relapsed/refractory B-cell malignancies

Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma

ZUMA-12: A phase 2 study of axi-cel as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL)

Potentially targetable pathways ID’d for augmenting CAR-T cell therapy for DLBCL

Mosunetuzumab induces deep and durable remissions in 3L R/R follicular lymphoma

Study indicates circulating tumour cell assessment should be part of multiple myeloma diagnostic workup